{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:12:52Z","timestamp":1783476772367,"version":"3.55.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jacc.2019.07.030","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T14:24:44Z","timestamp":1567434284000},"page":"1366-1375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Impaired Spontaneous\/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?"],"prefix":"10.1016","volume":"74","author":[{"given":"Diana A.","family":"Gorog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.07.030_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jacc.2015.02.040","article-title":"Endogenous fibrinolysis an important mediator of thrombus formation and cardiovascular risk","volume":"65","author":"Okafor","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.030_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ahj.2008.03.018","article-title":"Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments","volume":"156","author":"Bainey","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.07.030_bib3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/0735-1097(89)90325-2","article-title":"Acute myocardial infarction: a failure of timely, spontaneous thrombolysis","volume":"13","author":"Swan","year":"1989","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.030_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/eurheartj\/ehy760","article-title":"Endogenous fibrinolysis in STEMI: important before and after primary PCI","volume":"40","author":"Sinnaeve","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.07.030_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.thromres.2004.12.007","article-title":"The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project","volume":"116","author":"Nordenhem","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2796.2000.00604.x","article-title":"Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study","volume":"247","author":"Gram","year":"2000","journal-title":"J\u00a0Int Med"},{"key":"10.1016\/j.jacc.2019.07.030_bib7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.CIR.0000134965.73212.A6","article-title":"Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women","volume":"110","author":"Pradhan","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.07.030_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/HJR.0b013e3280e129d0","article-title":"Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women\u2019s Heart and Health cohort study","volume":"14","author":"May","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.jacc.2019.07.030_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.02.002","article-title":"Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study","volume":"140","author":"Tofler","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.atherosclerosis.2009.03.020","article-title":"Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study","volume":"206","author":"Kinlay","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2019.07.030_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.atherosclerosis.2006.11.005","article-title":"Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty","volume":"196","author":"Lee","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2019.07.030_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/hrt.2005.061895","article-title":"PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting","volume":"92","author":"Marcucci","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2019.07.030_bib13","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jacc.2009.11.095","article-title":"Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease","volume":"55","author":"Gorog","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.030_bib14","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jth.13135","article-title":"Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction","volume":"13","author":"Leenaerts","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1046\/j.1365-2141.2003.04549.x","article-title":"Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system","volume":"122","author":"Zorio","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2019.07.030_bib16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1055\/s-0037-1613387","article-title":"Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study","volume":"89","author":"Morange","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib17","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/01.ATV.0000015445.22243.F4","article-title":"Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe","volume":"22","author":"Juhan-Vague","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.07.030_bib18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2008.002386","article-title":"Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men","volume":"94","author":"Meltzer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2019.07.030_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1160\/TH04-08-0497","article-title":"Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact","volume":"94","author":"Fr\u00e8re","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1053\/euhj.1999.2013","article-title":"Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men","volume":"21","author":"Muscari","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.07.030_bib21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00125-014-3267-z","article-title":"Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3","volume":"57","author":"Hess","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.07.030_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/1479164111432788","article-title":"Complement C3 is a novel plasma clot component with anti-fibrinolytic properties","volume":"9","author":"Howes","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib23","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0140-6736(15)60372-5","article-title":"Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes","volume":"385 Suppl 1","author":"King","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.07.030_bib24","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1056\/NEJMoa055373","article-title":"Multiple biomarkers for the prediction of first major cardiovascular events and death","volume":"355","author":"Wang","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.030_bib25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/CIRCULATIONAHA.117.029901","article-title":"D-dimer predicts long-term cause-specific mortality, cardiovascular events, and cancer in patients with stable coronary heart disease","volume":"138","author":"Simes","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.07.030_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.thromres.2013.09.033","article-title":"Age- and sex-dependent reference intervals for D-dimer: evidence for a marked increase by age","volume":"132","author":"Haase","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/ehjcvp\/pvv039","article-title":"The current role and future prospects of D-dimer biomarker","volume":"2","author":"Soomro","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2019.07.030_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/ijlh.12665","article-title":"Review of D-dimer testing: good, bad, and ugly","volume":"39 Suppl.1","author":"Linkins","year":"2017","journal-title":"Int J Lab Haematol"},{"key":"10.1016\/j.jacc.2019.07.030_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.thromres.2015.11.031","article-title":"Harmonisation of D-dimer - a call for action","volume":"137","author":"Longstaff","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib30","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5551\/jat1994.2.Supplement1_S5","article-title":"Lipoprotein (a) in the regulation of fibrinolysis","volume":"2 Suppl 1","author":"Edelberg","year":"1995","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jacc.2019.07.030_bib31","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.CIR.88.3.935","article-title":"Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction","volume":"88","author":"Moliterno","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.07.030_bib32","first-page":"456189","article-title":"Increased oxidation as an additional mechanism underlying reduced clot permeability and impaired fibrinolysis in type 2 diabetes","volume":"2015","author":"Lados-Krupa","year":"2015","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Collaboration","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.07.030_bib34","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.030_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-016-0258-8","article-title":"The relationship between Lp(a) and CVD outcomes: a systematic review","volume":"15","author":"Forbes","year":"2016","journal-title":"Lipids Health Dis"},{"issue":"9","key":"10.1016\/j.jacc.2019.07.030_bib36","article-title":"Twenty-year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish Heart Health Extended Cohort (SHHEC)","volume":"6","author":"Tunstall-Pedoe","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.07.030_bib37","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1161\/ATVBAHA.107.153221","article-title":"Heritability of clot formation, morphology, and lysis: the EuroCLOT study","volume":"27","author":"Carter","year":"2007","journal-title":"Arterioscler Thromb Vasc Viol"},{"key":"10.1016\/j.jacc.2019.07.030_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.transci.2018.02.020","article-title":"A\u00a0new assay for Global Fibrinolysis Capacity (GFC): investigating a critical system regulating hemostasis and thrombosis and other extravascular functions","volume":"57","author":"Amiral","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jacc.2019.07.030_bib39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1160\/TH13-04-0345","article-title":"Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis","volume":"110","author":"Matsumoto","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/jth.13957","article-title":"Measuring fibrinolysis: from research to routine diagnostic assays","volume":"16","author":"Longstaff","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/vcp.12534","article-title":"Preanalytic processing of rat plasma influences thrombin generation and fibrinolysis assays","volume":"46","author":"Brooks","year":"2017","journal-title":"Vet Clinical Pathol"},{"key":"10.1016\/j.jacc.2019.07.030_bib42","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/jth.14002","article-title":"An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH","volume":"16","author":"Pieters","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib43","first-page":"CD010438","article-title":"Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma-induced coagulopathy in adult trauma patients with bleeding","author":"Hunt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2019.07.030_bib44","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1161\/ATVBAHA.118.311178","article-title":"Microfluidic modeling of thrombolysis","volume":"38","author":"Loyau","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.07.030_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2016.09.002","article-title":"Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model","volume":"146","author":"Hosokawa","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib46","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehs300","article-title":"Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease","volume":"34","author":"Sharma","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.07.030_bib47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.2008.07569.x","article-title":"Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men","volume":"145","author":"Meltzer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2019.07.030_bib48","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.ATV.0000241589.52950.4c","article-title":"Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis","volume":"26","author":"Collet","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.07.030_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2141.2008.07568.x","article-title":"Hypofibrinolysis is a risk factor for arterial thrombosis at young age","volume":"145","author":"Guimar\u00e3es","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2019.07.030_bib50","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1160\/TH11-11-0760","article-title":"Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction","volume":"107","author":"Leander","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1160\/TH14-01-0032","article-title":"Fibrin clot properties and their modulation in thrombotic disorders","volume":"112","author":"Undas","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2010.09.011","article-title":"Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke","volume":"127","author":"Rooth","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib53","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"Saraf","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.030_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurheartj\/ehy656","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","volume":"40","author":"Farag","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.07.030_bib55","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.07.030_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.jacc.2019.07.030_bib57","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/ATVBAHA.114.304530","article-title":"Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating \u03b12-antiplasmin","volume":"34","author":"Reed","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.07.030_bib58","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/ATVBAHA.109.183707","article-title":"Effects of aspirin on clot structure and fibrinolysis using a novel in\u00a0vitro cellular system","volume":"29","author":"Ajjan","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.07.030_bib59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1160\/TH12-06-0441","article-title":"Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions","volume":"109","author":"Hosokawa","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","article-title":"P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries","volume":"112","author":"Andre","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2019.07.030_bib61","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12265-017-9746-0","article-title":"Disaggregation following agonist-induced platelet activation in patients on dual antiplatelet therapy","volume":"10","author":"Wadowski","year":"2017","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib62","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2018.11.023","article-title":"Effect of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis","volume":"173","author":"Spinthakis","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib63","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/09537100500163226","article-title":"Glycoprotein IIb\/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses","volume":"16","author":"Judge","year":"2005","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2019.07.030_bib64","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2004.02.059","article-title":"Ability of anti-glycoprotein IIb\/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions","volume":"44","author":"Goto","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.030_bib65","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1538-7836.2009.03432.x","article-title":"Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab","volume":"7","author":"Speich","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib66","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1538-7836.2010.03739.x","article-title":"Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor","volume":"8","author":"Ammollo","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib67","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1111\/jth.14281","article-title":"Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity","volume":"16","author":"Carter","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib68","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10238-018-0490-9","article-title":"Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation","volume":"18","author":"K\u00f6nigsbr\u00fcgge","year":"2018","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jacc.2019.07.030_bib69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11239-019-01851-8","article-title":"A\u00a0direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor","volume":"48","author":"Morishima","year":"2019","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2019.07.030_bib70","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11239-016-1399-3","article-title":"Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation","volume":"42","author":"Lau","year":"2016","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2019.07.030_bib71","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bcp.13440","article-title":"Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium","volume":"84","author":"\u00c1lvarez","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2019.07.030_bib72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2015.12.023","article-title":"Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation","volume":"138","author":"Semeraro","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/09537104.2016.1158402","article-title":"Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation","volume":"27","author":"Farag","year":"2016","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2019.07.030_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euz176","article-title":"Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation","author":"Spinthakis","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2019.07.030_bib75","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.030_bib76","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.030_bib77","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2165\/00003495-200363170-00005","article-title":"Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes","volume":"63","author":"Krysiak","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2019.07.030_bib78","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2019.07.030_bib79","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0038-1676863","article-title":"PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention","volume":"119","author":"Paciullo","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib80","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cvr\/cvu137","article-title":"High-density lipoprotein as a modulator of platelet and coagulation responses","volume":"103","author":"van der Stoep","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/ATVBAHA.117.309664","article-title":"2017 Scientific Sessions Sol Sherry distinguished lecture in thrombosis: factor XI as a target for new anticoagulants","volume":"38","author":"Weitz","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.07.030_bib82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14728214.2019.1591368","article-title":"Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation","volume":"24","author":"Sz\u00e9kely","year":"2019","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jacc.2019.07.030_bib83","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.117.312012","article-title":"Novel antithrombotic drugs on the horizon: the ultimate promise to prevent clotting while avoiding bleeding","volume":"121","author":"McFadyen","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2019.07.030_bib84","doi-asserted-by":"crossref","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","article-title":"A\u00a0factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacc.2019.07.030_bib85","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/jth.13658","article-title":"A\u00a0first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects","volume":"15","author":"Zhou","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.030_bib86","series-title":"Principles and practice of screening for disease","author":"Wilson","year":"1968"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719359613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719359613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:25:06Z","timestamp":1760016306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719359613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0735109719359613"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.07.030","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impaired Spontaneous\/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}